Abstract
The outbreak of the coronavirus disease (COVID-19) had put vaccine research and development (R&D) on the urgent agenda. China had taken a diversified route in vaccine research and development. It had taken an approach of first producing inactivated vaccines and then tackling mRNA vaccines, and had achieved varying degrees of progress. At present, the scale of production and the number of vaccines in China is very large, which helped to form an immune barrier. However, China's participation in international vaccine cooperation and exporting vaccines still faced some challenges, and efforts were needed to improve the effectiveness of vaccines and ensure the improvement of vaccine upgrade.
Get full access to this article
View all access options for this article.